Structural heart disease: the year in valvular and complex coronary intervention trials

J Thorac Dis. 2020 May;12(5):2910-2918. doi: 10.21037/jtd.2019.12.138.


The need for treatment strategies targeting complex structural heart and obstructive epicardial coronary artery disease (CAD) is rapidly growing. The demographics in referral centers has shifted to an older population with greater co-morbidities and higher risk. Indeed, nearly one quarter of patients in tertiary-care settings have moderate or severe valvular heart disease, and despite a decrease in overall CAD burden in the United States over the past two decades the prevalence of myocardial infarction remains high. The 2019 societal scientific sessions included novel research and landmark presentations on less invasive valvular and safer complex coronary interventions in the aforementioned populations, in hopes of improving patient outcomes and expanding treatment indications. Transcatheter aortic valve replacement (TAVR), percutaneous mitral and tricuspid valve therapy, and complex coronary interventions, were the focus of important clinical trials and registry data. Herein, we provide a select and concise review of the most pivotal studies presented.

Keywords: COAPT; MitraClip; PARTNER; Percutaneous coronary intervention (PCI); transcatheter aortic valve replacement (TAVR).

Publication types

  • Review